Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses
Clinical & Experimental Allergy · 2026
DOI: 10.1111/cea.70299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, 2026. Verfasst von Ritesh Agarwal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Bronchiectasis, Aspergillosis, Allergic Bronchopulmonary, Aspergillus fumigatus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Whether allergic bronchopulmonary aspergillosis (ABPA) causes bronchiectasis or merely represents Aspergillus fumigatus colonisation of damaged airways remains debated. Establishing causality is challenging because airway damage is predominantly driven by host immune responses rather than by direct fungal invasion. We systematically evaluate four competing hypotheses: (i) ABPA causes bronchiectasis, (ii) reverse causation, with bronchiectasis predisposing to ABPA, (iii) a shared underlying factor independently producing both conditions and (iv) a spurious association. We evaluate radiological, pathological, immunological, temporal and therapeutic evidence in relation to these hypotheses. The characteristic radiological phenotype (central bronchiectasis and high‐attenuation mucus), eosinophil‐dominant histopathology and disease‐specific immunological profile (typically absent in other forms of bronchiectasis despite Aspergillus colonisation) distinguish ABPA from incidental colonisation. Randomised controlled trials demonstrating that antifungal treatment or anti‐inflammatory therapy (glucocorticoids and biological agents) improve clinical and immunological outcomes argue against a purely spurious association. Temporal observations indicate that ABPA precedes bronchiectasis in many cases. While uncertainty remains and host susceptibility is likely essential, the available evidence suggests that ABPA contributes to bronchiectasis through antigen‐driven immune injury, supporting the use of appropriate antifungal and immunomodulatory therapy in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Monash Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne, Australia.
ORCID-Profile: Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, Philip Bardin
Zitieren
APA
Agarwal, R., Sehgal, I. S., Muthu, V., & Bardin, P. (2026). Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70299
Vancouver
Agarwal R, Sehgal IS, Muthu V, Bardin P. Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70299
BibTeX
@article{Agarwal2026,
author = {Agarwal, Ritesh and Sehgal, Inderpaul Singh and Muthu, Valliappan and Bardin, Philip},
title = {Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses},
journal = {Clinical & Experimental Allergy},
year = {2026},
doi = {10.1111/cea.70299}
}
EUVIMED